These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 30610540)

  • 41. Screening Medications for the Treatment of Cannabis Use Disorder.
    Panlilio LV; Justinova Z; Trigo JM; Le Foll B
    Int Rev Neurobiol; 2016; 126():87-120. PubMed ID: 27055612
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal.
    Allsop DJ; Lintzeris N; Copeland J; Dunlop A; McGregor IS
    Clin Pharmacol Ther; 2015 Jun; 97(6):571-4. PubMed ID: 25777582
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis.
    Morgan CJ; Curran HV
    Br J Psychiatry; 2008 Apr; 192(4):306-7. PubMed ID: 18378995
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cannabinoid receptor binding and mRNA levels in several brain regions of adult male and female rats perinatally exposed to delta9-tetrahydrocannabinol.
    García-Gil L; Romero J; Ramos JA; Fernández-Ruiz JJ
    Drug Alcohol Depend; 1999 Jun; 55(1-2):127-36. PubMed ID: 10402157
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prenatal cannabis exposure - The "first hit" to the endocannabinoid system.
    Richardson KA; Hester AK; McLemore GL
    Neurotoxicol Teratol; 2016; 58():5-14. PubMed ID: 27567698
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neurobiology of cannabis addiction.
    Jain R; Balhara YP
    Indian J Physiol Pharmacol; 2008; 52(3):217-32. PubMed ID: 19552052
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adverse effects of cannabis.
    Prescrire Int; 2011 Jan; 20(112):18-23. PubMed ID: 21462790
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification (Part II): Psychiatric complaints and their relation to delta-9-tetrahydrocannabinol and its metabolites in serum.
    Bonnet U; Borda T; Scherbaum N; Specka M
    Drug Alcohol Depend; 2015 Oct; 155():302-6. PubMed ID: 26298553
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Spontaneous network activity of cerebellar granule neurons: impairment by in vivo chronic cannabinoid administration.
    Ghozland S; Aguado F; Espinosa-Parrilla JF; Soriano E; Maldonado R
    Eur J Neurosci; 2002 Aug; 16(4):641-51. PubMed ID: 12270039
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neurological soft signs in non-psychotic patients with cannabis dependence.
    Dervaux A; Bourdel MC; Laqueille X; Krebs MO
    Addict Biol; 2013 Mar; 18(2):214-21. PubMed ID: 21054691
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cellular Mechanisms of Action of Drug Abuse on Olfactory Neurons.
    Heinbockel T; Wang ZJ
    Int J Environ Res Public Health; 2015 Dec; 13(1):ijerph13010005. PubMed ID: 26703658
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Driving Under the Influence of Marijuana Versus Driving and Dying Under the Influence of Marijuana: A Comparison of Blood Concentrations of Δ9-Tetrahydrocannabinol, 11-Hydroxy-Δ9-Tetrahydrocannabinol, 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol and Other Cannabinoids in Arrested Drivers Versus Deceased Drivers.
    Lemos NP; San Nicolas AC; Volk JA; Ingle EA; Williams CM
    J Anal Toxicol; 2015 Oct; 39(8):588-601. PubMed ID: 26378132
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Guanfacine Attenuates Adverse Effects of Dronabinol (THC) on Working Memory in Adolescent-Onset Heavy Cannabis Users: A Pilot Study.
    Mathai DS; Holst M; Rodgman C; Haile CN; Keller J; Hussain MZ; Kosten TR; Newton TF; Verrico CD
    J Neuropsychiatry Clin Neurosci; 2018; 30(1):66-76. PubMed ID: 28641496
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reversing the Psychiatric Effects of Neurodevelopmental Cannabinoid Exposure: Exploring Pharmacotherapeutic Interventions for Symptom Improvement.
    De Felice M; Laviolette SR
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360626
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term administration of Delta9-tetrahydrocannabinol desensitizes CB1-, adenosine A1-, and GABAB-mediated inhibition of adenylyl cyclase in mouse cerebellum.
    Selley DE; Cassidy MP; Martin BR; Sim-Selley LJ
    Mol Pharmacol; 2004 Nov; 66(5):1275-84. PubMed ID: 15286206
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics and pharmacodynamics of cannabinoids.
    Grotenhermen F
    Clin Pharmacokinet; 2003; 42(4):327-60. PubMed ID: 12648025
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Cannabis: Effects in the Central Nervous System. Therapeutic, societal and legal consequences].
    Rivera-Olmos VM; Parra-Bernal MC
    Rev Med Inst Mex Seguro Soc; 2016; 54(5):626-34. PubMed ID: 27428345
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [No opiates against cannabis hyperemesis syndrome].
    Bonnet U; Stratmann U; Isbruch K
    Dtsch Med Wochenschr; 2014 Feb; 139(8):375-7. PubMed ID: 24519114
    [TBL] [Abstract][Full Text] [Related]  

  • 59. General and oral health implications of cannabis use.
    Cho CM; Hirsch R; Johnstone S
    Aust Dent J; 2005 Jun; 50(2):70-4. PubMed ID: 16050084
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cannabis: pharmacology and toxicology in animals and humans.
    Adams IB; Martin BR
    Addiction; 1996 Nov; 91(11):1585-614. PubMed ID: 8972919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.